THF Residual Solvent Limits (ICH Q3C Class 2): What 720 ppm Means for Pharma Buyers

Tetrahydrofuran (THF, CAS 109-99-9) is a water-miscible cyclic ether with a boiling point of 66 °C and a vapour pressure of approximately 173 hPa at 20 °C. ICH Q3C(R8) assigns THF to Class 2, the solvents that require limitation but are not genotoxic carcinogens subject to Class 1 exclusion. The permitted daily exposure (PDE) for THF is 7.2 mg/day, and the Table 2 concentration limit is 720 ppm. At a patient dose of 10 g/day, a residual level of 720 ppm delivers exactly 7.2 mg of THF. The 720 ppm value is therefore a patient-exposure control derived from a standard daily dose, not an intrinsic property of the raw material. A certificate of analysis stating “THF ≤ 720 ppm” without a daily-dose context, validated method, and compendial chapter reference is incomplete.

The Class 2 designation separates THF from low-toxicity Class 3 solvents that are commonly controlled at 5000 ppm. THF cannot be reported as a lumped total volatile organic content value; it requires a separation and quantification step. A supplier result for total residual solvents by loss on drying is not equivalent to a THF determination and may miss a specific 720 ppm exceedance. In a multi-solvent process, co-eluting solvent peaks can also mask THF unless the chromatographic system is selectivity-tested.

For a buyer purchasing THF as bulk process solvent, the 720 ppm residual-solvent limit does not define bulk THF quality. Bulk THF specifications normally include assay, water, peroxide values, and stabilizer content. The residual-solvent limit applies to THF remaining in an API, excipient, or finished product after processing. Buyers should maintain two separate specification families: bulk solvent quality for incoming THF and residual-solvent testing for pharmaceutical articles. Confusing these two uses leads to audit observations because the analytical methods and acceptance limits are not interchangeable.

The binding regulatory trigger for residual-solvent testing is compendial. USP <467> and Ph. Eur. 2.4.24 describe headspace gas-chromatographic procedures for residual solvents. A buyer should require that the certificate of analysis report THF as µg/g or mg/kg on the as-is sample, not as solvent-free area percent. Since THF is volatile and water-miscible, static headspace GC with flame ionization detection is generally suitable, but sample dilution, equilibration temperature, pH, and ionic strength must be controlled to avoid partitioning errors. The method should have a limit of quantitation sufficiently below 720 ppm, preferably not more than 100 ppm, and linearity extending to at least 120% of the specification. A method validated only to 500 ppm cannot support an accept/reject decision at 720 ppm. Out-of-specification results require confirmation by gas chromatography with mass spectrometry to separate THF from co-eluting solvents or packaging-related artifacts.

During shipment and sampling, containers and closures can introduce THF-like artifacts. Rubber stoppers, adhesive labels, and plastic sample vials may release plasticizers or residual cyclic ethers into the headspace. The buyer should specify glass vials with inert septa, clean and conditioned according to the method, and require a laboratory blank with every sequence. A result reported as “THF not detected” must state the limit of quantitation. A “not detected” result with an LOQ of 500 ppm cannot demonstrate compliance with a 720 ppm limit.

Does 720 ppm Remain a Valid Release Limit When the Daily Dose Exceeds 10 g?

Under ICH Q3C Option 1, the Table 2 concentration limit for a Class 2 solvent applies directly to drug products with a daily dose of 10 g or less. When the administered daily dose is greater than 10 g, the concentration limit must be calculated using the equation: concentration limit in ppm = 1000 × 7.2 mg/day ÷ daily dose in g. For a 20 g/day product, the calculated ceiling is 360 ppm; for a 50 g/day product, it is 144 ppm. This calculation cascades into purchasing. An API released at 720 ppm may be acceptable in a 10 g/day product but can be unsuitable in a high-dose formulation. If a 20 g/day product contains 15 g of that API, the API alone contributes 10.8 mg/day of THF, exceeding the PDE of 7.2 mg/day before excipients are considered. Buyers should therefore define the material limit by working backward from the finished-product dose, using the formula and the actual component mass. The 720 ppm value is not an intrinsic property of the API; it is a fixed point on a dose-response calculation.

The same 720 ppm limit applies across dosage forms under ICH Q3C when the daily dose is 10 g or less; however, the analytical result depends on sampling the correct presentation. For a lyophilized product, THF may be below the release limit in the dried cake but present in the reconstitution vehicle. Buyers should sample the final dosage form in the presentation intended for administration. A result from a pre-lyophilization bulk solution may not be representative of the finished product because THF can partition during freezing and primary drying.

When a Single API Contains THF Alongside Dichloromethane or Toluene

Class 2 solvent compliance is not self-contained when a manufacturer uses multiple solvents. A batch may report THF at 600 ppm, dichloromethane at 450 ppm, and toluene at 500 ppm, each below its Table 2 concentration limit of 720 ppm, 600 ppm, and 890 ppm respectively. For a 10 g/day product containing 2 g of the API, the daily intakes are THF 1.2 mg, dichloromethane 0.9 mg, and toluene 1.0 mg. The corresponding PDEs are 7.2 mg/day, 6.0 mg/day, and 8.9 mg/day; the individual daily intakes are below the PDEs. If the API dose were 10 g/day, the same residue profile would deliver THF 6.0 mg, dichloromethane 4.5 mg, and toluene 5.0 mg; THF would remain below its PDE, but dichloromethane would reach 75% of its PDE and toluene 56% of its PDE, leaving little headroom for other components. A buyer cannot treat 720 ppm as a standalone raw-material pass criterion. Under Option 2, the daily intake of each Class 2 solvent from all ingredients must be evaluated against its own PDE, and the formulation risk assessment should include the combined solvent burden.

In production-scale agitated vacuum dryers operating at jacket temperatures of 40–60 °C and pressures of 10–40 mbar, crystalline APIs with low solvent affinity may release THF below 720 ppm over several hours. Amorphous intermediates, micronized powders, and hydrates may retain solvent through hydrogen bonding and high internal surface area, requiring longer drying or a solvent-replacement crystallization. Process variables such as bed depth, agitator speed, nitrogen bleed, and cake thickness influence residual solvent endpoints; a supplier's drying validation should include at least three consecutive production batches with headspace GC data. Published production-scale drying data for every API matrix is limited, so a buyer should request matrix-specific data rather than assume that the 720 ppm ICH limit guarantees identical drying behavior across different solid forms.

For process monitoring, transmission FTIR or near-infrared spectroscopy may be used to track THF in drying off-gas, but these are not substitutes for compendial headspace GC in release testing. Off-line GC-FID remains the regulatory expectation because it provides compound-specific quantification. Gas chromatography with thermal conductivity detection is generally not sensitive enough for residual THF at 720 ppm in the presence of water and other volatile solvents. The analytical laboratory should maintain method validation records under an ISO/IEC 17025 scope or equivalent quality system.

Peroxide Control and Stabilizer Declarations in Commercial THF Supply

Commercial THF intended for pharmaceutical use may be supplied unstabilized or stabilized with butylated hydroxytoluene (BHT). THF can undergo autoxidation to tetrahydrofuran hydroperoxide and other peroxide species on exposure to oxygen, light, or heat. In unstabilized THF, peroxide accumulation can create a safety hazard and can react with drug substances or catalysts during later processing; the supplier should provide a peroxide value, a retest date, and a storage statement on the certificate of analysis. Stabilized THF contains BHT, and BHT-stabilized commercial grades commonly contain approximately 250 ppm BHT. The exact BHT content and grade must be declared. If the downstream process is intolerant to BHT, unstabilized THF should be ordered in smaller package sizes and consumed within a defined interval under nitrogen. For either grade, the container must be closed immediately after sampling and protected from light.

For BHT-stabilized THF, a buyer should evaluate BHT carryover through process mass balance. If THF is used as a reaction solvent and removed to residue levels below 720 ppm, the BHT contribution is often low, but spray drying or film casting may concentrate non-volatile BHT in the final product. Published data for BHT carryover in all pharmaceutical process streams is limited; a buyer should request a supplier mass balance or perform a spiking study in the formulation.

THF has a flash point of approximately -14.5 °C closed cup and an autoignition temperature of approximately 321 °C. These limits matter for warehouse handling. The peroxide-prone nature of unstabilized THF means a nitrogen pad and a peroxide test interval are required; if a peroxide value exceeds the supplier's stated limit, the material should not be redistilled without an inhibitor because distillation can concentrate peroxides. This safety boundary is separate from the residual-solvent 720 ppm limit but can affect product quality if peroxides react with the API or degrade the solvent matrix.

A Compendial Limit Does Not Define the Analytical Procedure

The 720 ppm limit has operational meaning only when the analytical method is specified. A buyer-facing specification should state the test method, the sample dissolution or dilution approach, the headspace parameters, and the calibration strategy. For water-soluble samples, water-based dilution may be used; for water-insoluble samples, a high-boiling polar solvent such as dimethylformamide may be required. The chosen procedure must be validated for the specific matrix, not simply transferred from a pharmacopeial reference. Recovery in spiked samples should be within a defined range, typically 80–120%, and injection reproducibility should be demonstrated. A certificate of analysis that reports “THF not detected” must also state the limit of quantitation, because a method with an LOQ of 500 ppm cannot prove compliance with a 720 ppm limit. The buyer should require a method validation report or summary, especially for new polymorphs, amorphous solid dispersions, or micronized powders with high surface area.

At receiving, THF-containing raw materials should be sampled only after the container has equilibrated in a controlled environment, because condensation can affect the residual solvent result. THF drums or intermediate bulk containers should be stored in a flammable-liquids area with inert gas blanketing and proper bonding and grounding. Water ingress is an operational boundary because THF is hygroscopic and fully miscible with water; moisture can change the partitioning behavior in headspace GC analysis and can promote phase separation in later solvent-recovery operations. Gaskets, sampling lines, and seals should be selected for compatibility with cyclic ethers to avoid leaching plasticizer residues that may interfere with chromatographic baselines. If a supplier's release data show THF close to 720 ppm with an analytical uncertainty of approximately ±100 ppm, the buyer should evaluate process capability rather than relying on a single passing result. A one-sided material specification near the compendial limit may be statistically weak for critical drug products when multiple components contribute THF or when the manufacturing process includes a high-dose API.